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still fascinated by its magnitude, which 
included Southeastern Massachusetts 
between 1918 and 1920 (see Bridgewater 
Review, May 2016), and started a scien-
tific quest to identify and combat the 
infectious agent causing this devastating 
disease. In 2009, we experienced  
yet another big Flu scare with the  
so-called swine f lu, whose impact  
was fortunately much less disastrous 
than expected.
The Flu is caused by Inf luenza viruses, 
which originate in birds and have 
evolved to infect many wild and 
domesticated bird species, as well as 
pigs, horses, humans and even seals and 
whales. Until recently, scientists knew 
of only three major types of Inf luenza, 
named (unremarkably) Inf luenza A, 
B and C. In September 2016, a new 
Inf luenza virus isolated from pigs 
and cattle was officially classified as 
Inf luenza D. The various Inf luenza 
viruses impact human health somewhat 
differently. The biggest troublemaker 
is Inf luenza A, which infects multiple 
species and has the potential to become 
pandemic. Inf luenza B infection 
results in disease symptoms similar 
to Inf luenza A, but it does not cause 
pandemics since it infects only humans 
and seals, and thus is more containable. 
Inf luenza C causes mild non-seasonal 
disease and is not considered a serious 
health issue. Anti-Flu vaccines are man-
ufactured to confer immunity against 
selected strains of Inf luenza A and B, 
but not Inf luenza C. Although Flu 
viruses are among the best-understood 
infectious agents, medicine does not 
offer great tools to control them. The 
viruses simply change too often, thus 
requiring our immune systems to start 
working from scratch  
as soon as a new virus arises and forcing 
us to take a yearly vaccine in an attempt 
to protect ourselves. 
Just like any other virus, the structure 
of Inf luenza virus can be summarized 
as “a piece of bad news wrapped in 
a protein” (Peter Medawar, National 
Geographic, 1994). In fact, Inf luenza A 
viruses have eight pieces of bad news, 
each made of ribonucleic acid (RNA). 
RNA is similar to deoxyribonucleic 
acid (DNA) and contains the viral 
genetic code. Each piece of RNA is 
wrapped in a proteinaceous coat, and 
all eight pieces are held together by a 
membrane-like structure, called an 
envelope (Figure 1, in purple). The 
outside surface of the virus is spiky 
(Figures 1 and 2), which allows it to 
attach to the surface of cells in our 
respiratory tract. The spike responsible 
for the attachment is a protein molecule 
called Hemagglutinin (H, in orange, 
Figure 1), which works like velcro. It 
is “sticky” because it can interact with 
molecules on the cell surface (sialic 
acid or SA) that serve as viral recep-
tors. Once the H and SA “velcro” 
together, the cellular membrane bulges 
inward and the Inf luenza virus finds 
itself wrapped in a “bubble” inside the 
host cell. RNA genetic code directs 
the host cell to produce multiple cop-
ies of all viral components, which are 
then packaged as new viruses. The 
new viruses are released when they 
are “pinched out” from the cell. The 
enzyme Neuronimidase (Figure 1, in 
blue), is essential for the process, helping 
the new viruses escape the velcro of the 
cellular surface. The infected cell con-
tinues to produce viruses until it runs 
out of membrane material and then 
dies, while the new viruses go on to 
infect neighboring cells or are released 
into the environment by coughing and 
sneezing. 
The Inf luenza A and B viruses 
propagate very quickly and trigger 
a robust immune response, which 
we experience as high fever and 
inf lammation of the respiratory tract. 
Normally, the first exposure to a 
virus or taking a vaccine will build 
immunity and protect our bodies from 
future infections. Unfortunately, that 
is not exactly true for the Flu. The 
trouble is that the molecular machinery 
copying Inf luenza genetic code is 
“sloppy” and makes a lot of errors. As 
a result, Inf luenza viruses constantly 
change and reinvent themselves into a 
multiplicity of different versions, such 
as H1N1, H1N5 and many others. The 
letters H and N refer to the viral spikes, 
hemagglutinin and neuronimidase, 
which comprise the viral portrait from 
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It is hardly necessary to introduce the Flu: everyone fears getting it or knows someone who has had  the misfortune of experiencing it. Every year,  
many of us debate with our relatives, our physicians 
and ourselves whether to get the anti-Flu vaccine.  
The impact of the Flu on our lives can be illustrated 
with numbers involving many zeros: yearly, thousands  
of people lose their lives to the Flu or complications 
from the Flu; millions of doctor’s office visits take 
place; billions of dollars are spent dealing with the  
Flu; and countless hours of work and school are 
lost recovering from it. Almost a century after the 
pandemic Spanish f lu ravaged the world, we are 
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drugs block the release of the army of 
newly produced viruses from infected 
cells, thus stopping the infection at its 
roots. If taken past the onset of  
the symptoms, the drug still does its 
job, but does not deliver spectacular 
results simply because the body  
is already f looded with too many 
viruses to tackle. 
Major technological advances are in the 
works which, we hope, will improve 
our success rate of combating the Flu. 
No, there is no app for that; but the 
time has come for us to reach higher 
ground for managing the Flu. Those of 
us who have been getting the anti-Flu 
vaccine as recommended will have 
noticed over the last few years that 
things have changed for the better. 
The vaccine becomes available much 
earlier in the year (usually late August 
as opposed to October or November), 
and those who are allergic to eggs 
can now get vaccinated, which was 
not possible a few years ago. These 
improvements are a direct result of 
extensive efforts to advance technology 
for vaccine production and move the 
process away from eggs. For more than 
50 years, the vaccine was manufactured 
in eggs, simply because Inf luenza is 
a bird virus and readily propagates in 
that environment. Unfortunately, the 
Inf luenza virus also infects chickens 
the viewpoint of the immune system. 
Every time our body encounters 
Inf luenza virus, there is a good chance 
that it will be a new version, and thus 
previous illness or vaccine will not 
be relevant (or as relevant as it could 
be if the virus was not changing). An 
additional level of complexity comes 
from the fact that the Inf luenza virus 
has multiple pieces of “bad news” in 
its genetic makeup. If two different 
versions of Inf luenza virus happen to 
infect the same cell, RNA pieces can 
be mixed, thus increasing the diversity 
of newly made viruses even further. 
Generally, Inf luenza A viruses change 
faster than Inf luenza B, presumably 
due to their different abilities to infect 
various hosts. Inf luenza B infects 
mainly humans, and so it has a lower 
probability for producing new versions.
Our biological understanding of 
Inf luenza virus directly informs the 
methods that medical and public 
health officials use to deal with the 
Figure 2. Digitally-colorized Transmission 
Electron Microscope Image of H1N1 Influenza 
Virus Particles. Courtesy of National Institute of 
Allergy and Infectious Diseases. 
Flu globally. We take advantage of 
the seasonal nature of the Flu, which 
correlates with virus stability in the 
environment. The World Health 
Organization collects information 
regarding Inf luenza virus versions 
in different parts of the planet and 
recommends updates of the anti-Flu 
vaccine. For example, the high Flu 
season in the northern hemisphere 
spans the winter months; thus 
information about the current Flu 
strains collected in our winter (the 
southern hemisphere’s summer) is used 
to produce an updated vaccine for the 
southern hemisphere winter, and vice 
versa. As with many other disastrous 
phenomena, prevention of the Flu is 
our best bet. But unlike many other 
diseases, we do not have a vast array 
of tools to help patients with recovery. 
Only a single class of drugs, inhibitors 
of the N protein, is available on the 
market and they work well only if taken 
at the onset of Flu symptoms. The 
Figure 1. Creative Illustration of Influenza Virus. The surface glycoprotein spikes: emagglutinin 
and neuraminidase are displayed in orange and blue, respectively. The eight pieces of genetic  
code (not shown) are wrapped in the membrane of the viral envelope depicted in purple (Image by 
Kateryna Kon).
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and can wipe out huge numbers of 
them in a short time. When that 
happens, our capacity for producing 
anti-Flu vaccine is diminished, resulting 
in vaccine shortage, something that 
actually happened at the time of the 
swine Flu outbreak in 2009. Obviously, 
individuals allergic to eggs could 
not be vaccinated due to the risk of 
severe allergic reaction. The problem 
was solved with the development of 
methods to produce classical anti-Flu 
vaccine in tissue culture of mammalian 
cells and new types of vaccine based 
on recombinant proteins produced in 
a lab, neither of which involves eggs. 
An added bonus is the option to freeze 
mammalian cells and purified proteins 
to ensure adequate back-up resources 
for vaccine production, which was not 
possible with the old technology. 
While anti-Flu vaccine supply is no 
longer an issue, its effectiveness is a 
different story. The effectiveness rate 
of the anti-f lu vaccine is about 60%, 
which is understandable given the 
fact that Inf luenza viruses constantly 
change. In some years, the forecast of 
the most prevalent Inf luenza strains is 
off target and the vaccine effectiveness 
is lower. At present, not much can be 
done to improve that, since the virus 
strains cannot really be appreciated 
or changed before the Flu season is 
over. Naturally, the question “Does it 
make sense to get vaccinated?” arises. 
The records say “yes.” There is a great 
difference between the outcomes of 
Flu seasons before and after vaccine was 
made available. Even a 60%-effective 
vaccine helps combat the virus. When 
scientists compare the impact of the 
last pandemic Inf luenza strain—the 
swine f lu of 2009—with previous 
ones, they see a huge contrast. In the 
2009 pandemic, the human death 
toll was much smaller, at least in part 
due to “leftover” protection from 
past vaccines. The development of a 
universal anti-Flu vaccine protecting 
against all Flu viruses seems like a 
perfect solution and hopes are on 
the rise due to recent technological 
advancements. Biologists’ analyses 
of mutations in Flu spikes reveal that 
certain parts of them do not tolerate 
change. These parts are not “protected” 
from mutations; rather, even slight 
changes in them destabilize the virus—
just like even small alterations in the 
key beams of a house will result in 
its collapse. Currently, scientists are 
working to generate a vaccine targeting 
these unchanging, or constant regions 
of Flu spikes, thus hoping to find 
universal protection against the forever-
evolving Flu. So far, experiments in 
mice look promising.
Another avenue to diminish the impact 
of the Flu on our society is to increase 
the vaccination rates, thus minimizing 
chances for virus transmission. Painless 
microneedle patches for syringe-free 
vaccine delivery are in human clinical 
trials both in the US and Europe 
and are expected to revolutionize 
vaccination not only for individuals 
with needle-phobia, but globally. It is 
hoped that, one day, patches will be 
paired with vaccines that do not require 
refrigeration and will be delivered by 
mail to our homes for self-application, 
thus saving us trips to the doctor’s 
office, time and travel resources 
(especially in rural areas). New ideas are 
being explored involving social media 
and big-data approaches for the purpose 
of Flu tracking and forecasting, such 
as Google Flu Trends, Flu Outlook 
(Northeastern University, Boston) 
and FluNearYou (Boston Children’s 
Hospital). While all advancements 
toward combating the Flu are exciting 
and have great potential to improve our 
lives, it is important to emphasize that 
they are not justification for skipping 
the simple and low-cost tools we always 
have at our disposal. Believe it or not, 
frequent hand-washing, covering our 
mouths and noses when sneezing or 
coughing, not touching our faces, and 
staying home until our fever is gone can 
make a huge difference.
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of the most prevalent Inf luenza 
strains is off target and the vaccine 
effectiveness is lower. 
